Contact Information

Professional Experience


  • 2008 - present, Professor, Cancer Biology, Beckman Research Institute of City of Hope, Duarte, CA
  • 2006 - 2008, Senior Vice President for Academics, City of Hope
  • 2004 - 2007, Associate Director, Beckman Research Institute of City of Hope, Duarte, CA
  • 2003 - 2004, Associate Dean, Graduate Studies and Research, California State University, Los Angeles
  • 2001 - 2003, Professor and Chair, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2000 - 2001, Professor, Cell & Tumor Biology, City of Hope, Duarte, CA
  • 1996 - 2000, Associate Professor, Cell & Tumor Biology, City of Hope, Duarte, CA
  • 1990 - 1996, Assistant Professor, Cell & Tumor Biology, City of Hope, Duarte, CA
  • 1990, Staff Fellow, NIH/NCI, Bethesda, MD
  • 1987 - 1990, American Cancer Society Postdoctoral Fellow, NIH/NCI, Bethesda, MD
  • 1980 - 1986, NIH Predoctoral Fellow, Dept. of Biology, Johns Hopkins Univ., Baltimore, MD

Education

 
Education/Training
  • 1987 - 1990, National Cancer Institute, Bethesda, MD. Postdoctoral, Molecular Biology
  • 1986, Johns Hopkins University, Baltimore, MD. Ph.D., Biology
  • 1979, Stanford University, Stanford, CA. B.S., Biology
 

Honors/Awards

 
Awards
  • 2012-pres, Director, City of Hope-San Gabriel Valley Science Education Partnership Award (SEPA) Collaborative
  • 2006 - 2011, Co-Director, California State University-Los Angeles and City of Hope Cancer Collaborative
  • 2000 - 2003, Director, Training Program in Breast Cancer Research
  • 1992 - 1994, American Cancer Society Junior Faculty Award
  • 1979, Phi Beta Kappa, Stanford University

Honors
  • 2012, “It Takes A Village” honoree, Duarte Education Foundation
  • 2010, Woman of Achievement, Young Women's Christian Association (YWCA) of San Gabriel Valley, CA
  • 2006, Woman of the Year in Science and Technology, State Legislator’s Office, CA
 
 

Publications

 
This is a partial list of publications. For a full list of publications, please click here.
  • Gu, L., Chen, J., Synold, T.W., Forman, B.M. and Kane, S.E. (2013) Bioimaging PXR-dependent mdr1a gene regulation in live animals. J Pharmacol Exp Ther.  345: 438-445.  doi:10.1124/jpet.113.203562
  • Sadava, D. and Kane, S.E. (2013) Silibinin reverses drug resistance in human small-call lung carcinoma cells. Cancer Lett. 339: 102-106. doi: 10.1016/j.canlet.2013.07.017
  • Somlo, G., Martel, C.L., Lau, S.K., Frankel, P., Ruel, C., Gu, L., Hurria, A., Chung, C., Luu, T., Morgan, R., Leong, L., Koczywas, M., McNamara, M., Russell, C.A., Kane, S.E. (2012) A phase I/II prospective, single arm trial of gefitinib, trastuzumab and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Res. Treat. 131: 899-906.
  • Gu, L., Lau, S.K., Loera, S., Somlo, G. and Kane, S.E. (2009) Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. Clin. Cancer Res. 15: 7196-7206.
  • Gu, L., Waliany, S. and Kane, S.E. (2009) Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and Herceptin resistance. PLoS ONE 4: e6220.
  • Gu, L., Tsark, W.M., Brown, D.A., Blanchard, S., Synold, T.W. and Kane, S.E. (2009) A new model for studying tissue-specific mdr1a expression in vivo by live imaging. Proc. Natl. Acad. Sci. USA 106: 5394-5399.
  • Sadava, D., Still, D., Mudry, R.R. and Kane, S.E. (2009) Effect of Ganoderma extracts on drug-sensitive and multidrug resistant small-cell lung carcinoma cells. Cancer Lett. 277: 182-189.
  • Sadava, D., Whitlock, E. and Kane, S.E. (2007) The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem. Biophys. Res. Comm. 360: 233-237.
  • Kane, S.E. (2006) Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opin. Ther. Patents 16: in press. Invited review.
  • Chan, C.T., Metz, M.Z. and Kane, S.E. (2005) Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res. Treat. 91: 187-201.
  • Schwarz, R.E., Donohue, C.A., Sadava, D., and Kane, S.E. (2003) Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment. Cancer Lett. 189: 59-68.
  • Sadava, D., Coleman, A.B. and Kane, S.E. (2002) Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J. Liposome Res. 12: 301-309.
  • Coleman, A.B., Metz, M.Z., Donohue, C.A., Schwarz, R.E., and Kane, S.E. (2002) Chemosensitization by fibroblast growth factor-2 is not dependent on proliferation, S-phase accumulation or p53 status. Biochem. Pharmacol. 64: 1111-1123.
  • Sadava, D., Ahn, J., Zhan, M., Pang, M.-L., Ding, J., and Kane, S.E. (2002) Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Chemother. Pharmacol. 49: 261-266.
  • Sadava, D., Phillips, T., Lin, C. and Kane, S.E. (2002) Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 179: 151-156.
  • Kane, S.E., Matsumoto, L., Metz, M.Z., Donohue, C.A., Lingeman, R.G., Lin, S.W., and Doroshow, J.H. (2001) MDR1 bicistronic vectors: Analysis of selection stringency, amplified gene expression, and vector stability in cell lines. Biochem. Pharmacol. 62: 693-704.
  • Coleman, A.B., Momand, J., and Kane, S.E. (2000) Basic fibroblast growth factor sensitizes NIH 3T3 cells to apoptosis induced by cisplatin. Molec. Pharmacol. 57: 324-333.

Research

 
To read more about Dr. Kane's research, please click here